Clinical Trial

Long-term Safety and Tolerability of HRS-5965 in Patients With Paroxysmal Nocturnal Hemoglobinuria

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a multicenter, single-arm, open-label study. Patients with Paroxysmal Nocturnal Hemoglobinuria who had previously received and completed the HRS-5965 study well included. All eligible subjects received HRS-5965 tablets or capsules until the end of treatment in this study.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-01-31; most recent amendment 2025-12-18.
Status change: Recruiting → Active, Not Recruiting 2025-12-18
Status change: Not Yet Recruiting → Recruiting 2024-04-10
Trial Details
NCT Number NCT06238544
Lead Sponsor Chengdu Suncadia Medicine Co., Ltd.
Conditions Paroxysmal Nocturnal Hemoglobinuria
Enrollment 132 participants
Start Date 2024-02-06
Primary Completion 2027-12 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2025-12-24